(Q61932366)
Statements
A Phase IV Randomised, Double-blind, Active and Placebo-controlled, 6-week Trial to Investigate the Efficacy and Safety of a Starting (and Fixed) Dose 0.25 mg Pramipexole (Mirapex®) in Patients With Idiopathic Restless Legs Syndrome (English)
0 references
September 2006
0 references
July 2007
0 references
404
0 references
18 year
0 references
80 year
0 references